JMP Securities Rates Werewolf Therapeutics Stock Outperform, Says Platform 'inovative' By | Old North State Wealth News
Connect with us

US News

JMP Securities rates Werewolf Therapeutics stock Outperform, says platform ‘inovative’ By



On Wednesday, JMP Securities initiated coverage on Werewolf Therapeutics Inc. (NASDAQ:HOWL) stock with a Market Outperform rating and set a price target of $12.00. The firm believes that Werewolf’s proprietary PREDATOR platform could mark a new chapter in the field of immunotherapy.

Werewolf Therapeutics, a biotechnology company, has been recognized for its innovative approach to cytokine-based therapies. JMP Securities’ evaluation is based on a combination of discounted earnings per share and revenue multiple analysis. This assessment reflects confidence in the company’s potential to overcome the challenges that have historically impeded the success of cytokine therapies in biotechnology.

The company’s lead product candidate, WTX-124, has demonstrated promising differentiation in preclinical trials when compared to the administration of IL-2. These results underpin the analyst’s positive outlook. Werewolf Therapeutics is also anticipated to release monotherapy dose-escalation results for WTX-124 and WTX-330 in the first half of 2024.

A strategic partnership with Jazz Pharmaceuticals (NASDAQ:) and a strong cash position, reported at $134.3 million, further bolster the company’s standing in the eyes of JMP Securities. The firm’s analysis suggests that Werewolf Therapeutics’ shares are currently undervalued, presenting an investment opportunity with a significant potential upside of approximately 296% and a downside risk of around 83%.

InvestingPro Insights

Werewolf Therapeutics Inc. (NASDAQ:HOWL) has caught the attention of JMP Securities, and a closer look at the company through InvestingPro’s lens provides additional insights. With a market capitalization of $258.99 million, the company holds a notable position in the biotech sector. However, InvestingPro data reveals a challenging financial landscape with a negative P/E ratio of -5.72, indicating that the company is not currently profitable. This is further supported by a gross profit margin of -95.09% for the last twelve months as of Q4 2023, suggesting significant costs relative to revenue.

InvestingPro Tips highlight that Werewolf Therapeutics holds more cash than debt, which is a positive sign of financial health. Moreover, the company’s liquid assets surpass its short-term obligations, providing some financial flexibility. Despite these strengths, analysts do not expect the company to be profitable this year, and a sales decline is anticipated. Yet, the stock has experienced a strong return over the last three months and an impressive 185.18% price uptick over the last six months, which may interest investors looking for growth potential in share price.

For those considering an investment in Werewolf Therapeutics, additional InvestingPro Tips can provide further guidance. There are 11 more tips available on InvestingPro, which could help investors make a more informed decision. To explore these tips and gain a deeper understanding of Werewolf Therapeutics, visit Use the coupon code PRONEWS24 to receive an additional 10% off a yearly or biyearly Pro and Pro+ subscription, offering even more insights to aid in your investment strategy.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Read the full article here

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *


Copyright © 2022 ONSWM News. Content posted on the Old North State Wealth News page was developed and produced by a third party news aggregation service. Old North State Wealth Management is not affiliated with the news aggregation service. The information presented is believed to be current. It should not be viewed as personalized investment advice. All expressions of opinion reflect the judgment of the authors on the date the articles were published. The information presented is not an offer to buy or sell, or a solicitation of any offer to buy or sell, any of the securities discussed.